Press Release

Private Equity specialists from Foot Anstey have advised the private investment company Ardian (in collaboration with GHO Capital) on the acquisition of Envision by the Envision Pharma Group’s leadership team from the Halifax Group.  Foot Anstey provided legal due diligence and project management alongside Ardian's other advisors.

Ardian is an independent private investment company with assets of US$55bn managed or advised in Europe, North America and Asia.  GHO Capital is a European specialist investor in healthcare headquartered in London.

Operating globally, Envision partners with medical affairs organisations providing scientific data communication services to biopharmaceutical and medical devices companies. Envision helps its clients commercialise new products via strategic data-communication planning, medical writing and medical communications services.

The Envision management team and employees, led by Brian Hepburn (CEO and founder), Greg Caswill (Chairman and founder), John Gillie (CFO), and Joseph Brown (President Envision Technology Solutions; ETS), will be reinvesting and continuing to lead the business in the next evolution of its growth.

Brian Hepburn, CEO of Envision, said: “This partnership with GHO Capital and Ardian provides the resources, expertise, and market knowledge for Envision to realise the next stage of its development and become the leading solution provider to the Medical Affairs departments within the biopharmaceutical industry. We are uniquely positioned to support our clients via our in-depth, strategically focused, scientific communication capabilities and expanding range of technology solutions. With the support of GHO Capital and Ardian, we will continue to invest in these core competencies and further extend the market reach of our enterprise technology platform, iEnvision™.”

Simon Cottle, Managing Director of Ardian Mid Cap Buyout in London, said: “After analysing the outsourced Medical Affairs services and software market, we identified Envision as having the highest potential for further growth. Their management team has done a great job in creating a market-leading proposition and we look forward to working with them in the next stage of the business’ development.”

Tags: CorporatePrivate Equity and Venture CapitalHealthcare2016